Form D · Biotechnology

Avitide, Inc.

Lebanon, NH · CIK 0001571506

Offering snapshot reported Oct 23, 2019 · SEC filing

Reported sold
$10M
Offering amount: $10M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 15, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 23, 2019Initial$9,999,796No comparison9SEC filing
Aug 24, 2018Initial$6,212,290No comparison4SEC filing
Jan 2, 2018Initial$3,999,983No comparison3SEC filing
Jun 27, 2017Initial$11,999,962No comparison10SEC filing
Aug 6, 2015Initial$3,831,920No comparison11SEC filing
Jun 9, 2014Initial$3,435,003No comparison7SEC filing
Mar 15, 2013Initial$1,449,999No comparison7SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-351722

Source: Form D, filed Oct 23, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Errik Anderson Director
Philip Ferneau Director
Tillman Gerngross Director
Colin Greenspon Director
Rishi Gupta Director
Kevin Isett Director, Executive
Kevin Issett Director, Executive
Scott Kennedy Executive
Warren Kett Executive
Claudio Nessi Director
Ian Ratcliffe Director
Michael Ross Director
Ajay Royan Director
Jon Sheller Executive
Jonathan Sheller Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
16 Cavendish Court
Lebanon, NH, 03766